{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/otitis-media-acute/prescribing-information/clarithromycin/","result":{"pageContext":{"chapter":{"id":"859385d7-8fde-5b5e-8357-c34d3500eeb7","slug":"clarithromycin","fullItemName":"Clarithromycin","depth":2,"htmlHeader":"<!-- begin field 52e8c7de-672e-49b1-80e8-a74c00d0e383 --><h2>Clarithromycin </h2><!-- end field 52e8c7de-672e-49b1-80e8-a74c00d0e383 -->","summary":"","htmlStringContent":"<!-- begin item ccff4889-3bfb-44c9-bad3-a74c00d0e2d5 --><!-- end item ccff4889-3bfb-44c9-bad3-a74c00d0e2d5 -->","topic":{"id":"0671aacb-4e00-5bb2-8b54-aa0da27fb4ab","topicId":"009f13e7-d649-401b-8b63-061c029e67f2","topicName":"Otitis media - acute","slug":"otitis-media-acute","lastRevised":"Last revised in January 2021","chapters":[{"id":"793c7288-db92-5c67-8ef6-0ea9a20f6b09","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0cbb536b-178c-5bea-a1c6-22c584a7e1b6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"944570b9-0a8f-5b67-8ee8-556c3fd8a613","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"aedad1bf-9c58-57d9-9c3d-d1fa6e40ee13","slug":"changes","fullItemName":"Changes"},{"id":"7bc4152c-a9f8-5afe-bb63-2a48a86ebf0d","slug":"update","fullItemName":"Update"}]},{"id":"cd84410b-569d-58a4-8fe8-c2eaed2ead26","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7875d022-7cbf-5961-a19e-d5987af92edc","slug":"goals","fullItemName":"Goals"},{"id":"8db5ac64-8db5-5daa-aa3c-d46caaf0abf3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3517d1cc-7aae-5036-81f5-ac0b590e84fd","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4ca0ace8-77fc-5319-95e0-e983fa092ed9","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f87cf2b3-b0ea-5485-b424-9518a3f586a2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e285c16b-d4ba-56b6-a3fd-3c27fc822357","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"749e39ba-56ce-5129-8e10-fef140b586c2","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9df3117d-949e-56bb-ac40-0393fb87071a","slug":"definition","fullItemName":"Definition"},{"id":"cb42b641-fdc3-5bd6-a13a-ca2c1edd9c21","slug":"causes","fullItemName":"Causes"},{"id":"2682b3f3-3099-54c9-9c02-867b7f3350e0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a7d4a184-6baa-5ae6-baef-11eba15038e6","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"fc412f0f-261f-5fae-a125-cfeefdd5e8b3","slug":"prognosis","fullItemName":"Prognosis"},{"id":"18e296ab-cfe3-58be-bf23-aaf4a6c6f49e","slug":"complications","fullItemName":"Complications"}]},{"id":"a0da1ac3-73ef-561b-9301-a1ccdf5fd8a8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"9e9b0e14-9f7d-5c5a-83a1-c4bfd193ba3d","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"7e76e099-c70a-5f57-b670-c0ad43913066","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0dac3638-3899-5899-bd0e-647894c3f003","fullItemName":"Management","slug":"management","subChapters":[{"id":"35db78a7-148c-5b20-8fd7-54ea5aaba599","slug":"acute-otitis-media-initial-presentation","fullItemName":"Scenario: Acute otitis media - initial presentation"},{"id":"4d27de1d-1fe0-5438-98c0-f85415825ca5","slug":"persistent-acute-otitis-media-treatment-failure","fullItemName":"Scenario: Persistent acute otitis media - treatment failure"},{"id":"7d848f0c-bb0a-5ea7-90f2-dd99a1cbc49e","slug":"recurrent-acute-otitis-media","fullItemName":"Scenario: Recurrent acute otitis media"}]},{"id":"c8285b67-3320-54ae-8537-4c0626e3632e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f512abb6-f15e-5fef-9f9d-23e008c401ff","slug":"analgesia","fullItemName":"Analgesia"},{"id":"15d20ee0-531c-5230-9e41-6194bfbe3614","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"859385d7-8fde-5b5e-8357-c34d3500eeb7","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"bb1b0220-4609-5ab7-8102-e31414c36dab","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"0f55a4d8-b11d-53a6-a26e-b2a9e98e8dd8","slug":"erythromycin","fullItemName":"Erythromycin"}]},{"id":"f43bc1b4-a67e-5bab-b27c-d141e7483b01","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"51596c5b-15a7-547d-bdcf-f7a467961cd7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f91fb8f9-4942-5683-8b3d-d8edd775f700","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c2fdf612-fff8-581e-bf78-7c9efcf08ddf","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2bb0e3c7-8948-5401-97a7-741ffa1d4477","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"570abb9c-faad-515e-86bb-0b947414dcb9","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5e5c540f-ce64-5768-9c46-dfde85f5364a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7f9af8df-6314-54fa-a769-b5bd0bd121ab","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c8285b67-3320-54ae-8537-4c0626e3632e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"f011de1e-99a4-5edd-ab3d-07f6e02f24c7","slug":"dosing-regime","fullItemName":"Dosing regime","depth":3,"htmlHeader":"<!-- begin field a64ae854-6a88-4c9d-8466-a74c00d156ef --><h3>Dosing regime</h3><!-- end field a64ae854-6a88-4c9d-8466-a74c00d156ef -->","summary":"","htmlStringContent":"<!-- begin item 80a71a62-2f4c-493c-b6bc-a74c00d15660 --><!-- begin field 25959e18-2837-4c51-b6ed-a74c00d156ef --><ul><li>The treatment duration for AOM is 5–7 days.</li><li><strong>In children,</strong> prescribe:<ul><li>Child 1 month to 11 years:<ul><li>Body weight under 8 kg: 7.5 mg/kg twice daily.</li><li>Body weight 8–11 kg: 62.5 mg twice daily.</li><li>Body weight 12–19 kg: 125 mg twice daily.</li><li>Body weight 20–29 kg: 187.5 mg twice daily.</li><li>Body weight 30–40 kg: 250 mg twice daily.</li></ul></li><li>Child 12–17 years: 250 mg twice daily, increased if necessary in severe infections to 500 mg twice daily.</li></ul></li><li><strong>In children with renal impairment,</strong> if estimated glomerular filtration rate (eGFR) is less than 30 mL/minute/1.73m<sup>2</sup>:<ul><li>Prescribe half the normal dose of clarithromycin.</li><li>Avoid <em>Klaricid XL</em>® or clarithromycin M/R preparations.</li></ul></li><li><strong>In adults, </strong>prescribe 250 mg twice daily, increased in severe infections to 500 mg twice daily.</li><li><strong>In adults with renal impairment,</strong> if the eGFR is less than 30 mL/minute/1.73m<sup>2</sup>:<ul><li>Prescribe half the normal dose of clarithromycin.</li><li>Avoid <em>Klaricid XL</em><sup>®</sup> or clarithromycin M/R preparations.</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">NICE, 2018a</a>]</p><!-- end field 25959e18-2837-4c51-b6ed-a74c00d156ef --><!-- end item 80a71a62-2f4c-493c-b6bc-a74c00d15660 -->","subChapters":[]},{"id":"331a1db4-04a0-5d96-9143-3900f60875aa","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field a29193b7-4098-48ea-a866-a74c00d16d9a --><h3>Contraindications and cautions</h3><!-- end field a29193b7-4098-48ea-a866-a74c00d16d9a -->","summary":"","htmlStringContent":"<!-- begin item e8e1b610-fb9e-445b-ad02-a74c00d16d03 --><!-- begin field 838c0aae-7693-4fb3-b820-a74c00d16d9a --><ul><li><strong>Do not prescribe c</strong><strong>larithromycin to people:</strong><ul><li>Taking drugs that prolong the QT interval (for example, terfenadine, and pimozide) — macrolides can also prolong the QT interval, which is a risk factor for Torsades de pointes.</li><li>With a history of QT prolongation or ventricular cardiac arrhythmia, including Torsades de pointes arrhythmias.</li><li>With severe hepatic failure in combination with renal impairment.</li><li>With hypokalaemia.</li></ul></li><li><strong>Prescribe clarithromycin with caution in people with:</strong><ul><li>Moderate to severe renal impairment.</li><li>Impaired hepatic function — clarithromycin is principally excreted by the liver. </li><li>Conditions which predispose to QT interval prolongation such as electrolyte disturbances (for example, hypomagnesemia).</li><li>Myasthenia gravis — macrolide antibiotics may aggravate the symptoms.</li><li>Coronary artery disease, severe cardiac insufficiency, or bradycardia (less than 50 beats per minute) — increased risk of QT prolongation.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">FDA, 2018</a>]</p><!-- end field 838c0aae-7693-4fb3-b820-a74c00d16d9a --><!-- end item e8e1b610-fb9e-445b-ad02-a74c00d16d03 -->","subChapters":[]},{"id":"ea141811-882f-575f-9121-d248722756e3","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field d474f570-6459-4412-9d76-a74c00d17d00 --><h3>Adverse effects</h3><!-- end field d474f570-6459-4412-9d76-a74c00d17d00 -->","summary":"","htmlStringContent":"<!-- begin item 6f69773a-7bac-45ae-bbe9-a74c00d17be8 --><!-- begin field 6dc48200-365d-458e-8287-a74c00d17d00 --><ul><li><strong>Nausea, vomiting, abdominal discomfort, and diarrhoea</strong> are the most common adverse effects of macrolides, but they are mild and less frequent with clarithromycin than with erythromycin.<ul><li>Consider pseudomembranous colitis if a person develops severe diarrhoea during or after treatment with clarithromycin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Anaphylaxis</strong> is rarely associated with clarithromycin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.</li><li><strong>Hepatotoxicity (including cholestatic jaundice) and rash</strong> have rarely been reported following treatment with erythromycin or clarithromycin.</li><li><strong>Reversible hearing loss (sometimes with tinnitus)</strong> can occur after large doses of erythromycin or clarithromycin.</li><li><strong>Other adverse effects reported rarely or very rarely include</strong> pancreatitis, QT interval prolongation, arrhythmias, Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">BNF 75, 2018</a>]</p><!-- end field 6dc48200-365d-458e-8287-a74c00d17d00 --><!-- end item 6f69773a-7bac-45ae-bbe9-a74c00d17be8 -->","subChapters":[]},{"id":"af51ccb6-0d19-5428-8093-7d686ced56c5","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 72ebd2f3-b946-4095-bbf0-a74c00d18b72 --><h3>Drug interactions</h3><!-- end field 72ebd2f3-b946-4095-bbf0-a74c00d18b72 -->","summary":"","htmlStringContent":"<!-- begin item e4f45411-a21d-4255-81dd-a74c00d18aea --><!-- begin field e073a03c-7bc1-4d14-8eca-a74c00d18b72 --><ul><li><strong>Calcium channel blockers (CCBs) </strong>— there is an increased risk of hypotension if CCBs, such as verapamil, amlodipine, and diltiazem are taken concomitantly with clarithromycin, as they are metabolised by CYP3A4. This may also lead to increased levels of clarithromycin.</li><li><strong>Ciclosporin </strong>— clarithromycin can increase ciclosporin levels. If co-administration of these drugs is necessary, ciclosporin levels should be monitored and the dose adjusted accordingly.</li><li><strong>Colchicine</strong> — colchicine toxicity has been reported with concomitant use of clarithromycin so the combination is contraindicated.</li><li><strong>CYP3A enzyme inducers </strong>(rifampicin, carbamazepine, phenobarbital) — these may induce the metabolism of clarithromycin, resulting in sub-therapeutic levels.<ul><li>It may be necessary to monitor the levels of these drugs, as CYP3A is inhibited by clarithromycin leading to higher plasma levels of the inducer.</li></ul></li><li><strong>Digoxin</strong> — clarithromycin increases digoxin levels. Monitor and reduce the digoxin dose if required.</li><li><strong>Edoxaban </strong>— levels may be increased by clarithromycin. </li><li><strong>Ergot alkaloids</strong> — concomitant administration is contraindicated, due to the risk of acute ergot toxicity.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of clarithromycin.<ul><li>However, women should be advised that if diarrhoea, vomiting or breakthrough bleeding occur there is a possibility of contraceptive failure. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>. </li></ul></li><li><strong>Oral hypoglycaemic drugs (sulfonylureas) and insulin </strong>— the concomitant use of clarithromycin and oral hypoglycaemic drugs and/or insulin can result in significant hypoglycaemia. Monitor glucose levels.</li><li><strong>Statins (atorvastatin, simvastatin) </strong>— these are extensively metabolised by CYP3A4. Concomitant administration with clarithromycin increases the plasma levels.<ul><li>Simvastatin — do not prescribe clarithromycin to a person taking simvastatin. If treatment with clarithromycin cannot be avoided, stop treatment with simvastatin temporarily.</li><li>Atorvastatin — avoid concurrent use with clarithromycin. If concurrent use cannot be avoided, prescribe the lowest dose of atorvastatin.</li></ul></li><li><strong>Warfarin </strong>— clarithromycin increases the anticoagulant effect of warfarin. Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li><li><strong>Drugs that prolong the QT interval </strong>(such as amiodarone, or sotalol) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is contraindicated.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">BNF 75, 2018</a>]</p><!-- end field e073a03c-7bc1-4d14-8eca-a74c00d18b72 --><!-- end item e4f45411-a21d-4255-81dd-a74c00d18aea -->","subChapters":[]},{"id":"3919b113-84bb-5fc8-b2c9-12cacf747a7f","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field bbd43d8a-9202-429d-8a56-a74c00d19fd5 --><h3>Pregnancy and breastfeeding</h3><!-- end field bbd43d8a-9202-429d-8a56-a74c00d19fd5 -->","summary":"","htmlStringContent":"<!-- begin item 0b59b2e3-5230-4e5b-aead-a74c00d19e90 --><!-- begin field 33c331d3-8ef6-4b58-838b-a74c00d19fd5 --><h4>Pregnancy</h4><ul><li>The safety of clarithromycin in pregnancy has not been established. Avoid (especially in the first trimester), unless the benefit outweighs the risks.</li></ul><h4>Breastfeeding</h4><ul><li>Clarithromycin is excreted into breastmilk. Avoid use in women who are breastfeeding, unless the benefits outweigh the risks.</li><li>The risk of infantile hypertrophic pyloric stenosis in infants might be increased by the use of maternal macrolides especially in infants exposed in the first 2 weeks after birth.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">Fenner, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/otitis-media-acute/references/\">BNF 75, 2018</a>]  </p><!-- end field 33c331d3-8ef6-4b58-838b-a74c00d19fd5 --><!-- end item 0b59b2e3-5230-4e5b-aead-a74c00d19e90 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}